The protective effect for renal function of Aliskiren in hypertensive CKD patients with proteinuria

Trial Profile

The protective effect for renal function of Aliskiren in hypertensive CKD patients with proteinuria

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Aliskiren (Primary) ; Calcium channel antagonists; Candesartan cilexetil; Losartan; Olmesartan medoxomil; Telmisartan; Valsartan
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Most Recent Events

    • 18 Jun 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
    • 14 Dec 2012 Planned end date changed from 1 Dec 2012 to 31 Dec 2013 as reported by University Hospital Medical Information Network - Japan.
    • 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top